The PROLONG randomized trial showed that a normal D-dimer (D-d) higher risk of recurrence (7/31; 27 percent patient-years; 95% CI:12-48) than patients in whom D-d remained normal at the 3 rd month and afterwards (4/149; 2.9 percent patientyears; 95% CI:1-7) (adjusted hazard ratio: 7.9; 95% CI:2
INTRODUCTION
The optimal duration of anticoagulation after a first episode of unprovoked venous thromboembolism (VTE) is still unknown [1] [2] [3] . Recently, the American College of Chest Physicians recommended that patients with unprovoked VTE should receive at least 3 months of anticoagulant therapy and then subjects should be evaluated for the risk-benefit ratio of long-term therapy 4 . Long term treatment is recommended in those in whom risk factors for bleeding are absent and for whom good anticoagulant monitoring is achievable.
In this recommendation, a relatively high value is attached to prevention of recurrent VTE and a lower value to the burden of long-term anticoagulant therapy. However, the decision about treatment is ultimately left to the physicians' subjective evaluation of the risk-benefit ratio in each patient and to patients' preferences about treatment prolongation. The risk of recurrence is greatest in the first 6 to 12 months after the initial episode while it gradually decreases thereafter 5 . As a result the benefits of extending anticoagulation may be offset over time by the risk of clinically important bleeding associated with vitamin K antagonists (VKAs) [1] [2] [3] 6, 7 . The identification of patient characteristics predictive of recurrence would be a valuable aid in the decision about stopping or prolonging VKAs after a first episode of unprovoked VTE. .
In subjects with normal D-d the rate of VTE recurrence was 4.4 percent patient-years (pt-y), which is higher than the expected annual rate of major bleeding (2 percent pt-y) with VKAs 6 . As a result, the optimal duration of treatment is an unresolved issue in these patients. In the PROLONG study only a single D-d measurement was performed after stopping anticoagulation and it is unknown whether and how often D-d becomes abnormal afterwards and whether a late hypercoagulability is associated with the risk of recurrences.
To address these questions, we conducted the observational multi-centre prospective PROLONG II study. In this study D-d was tested serially over a year in
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From subjects with normal D-d at one month after anticoagulation suspension for a first episode of unprovoked VTE with the aim of assessing the times and frequency of D-d becoming abnormal and its relation with recurrent VTE.
METHODS

Study patients
The PROLONG II study was a prospective cohort study in patients aged 18 to 82 years with a first episode of objectively documented symptomatic idiopathic VTE, either proximal lower extremity deep vein thrombosis (DVT) and/or pulmonary embolism (PE).
DVT was to be detected by compression ultrasonography or venography, and PE to be diagnosed on the basis of objective algorithms using clinical probability, ventilationperfusion or helical computed tomography lung scan, compression ultrasonography (if 
Study procedures
At the end of the intended anticoagulation period (T0), subjects were assessed for eligibility and baseline clinical conditions. The presence of known co-morbidities such as coronary heart disease, peripheral arterial disease, cerebrovascular disease, chronic intestinal inflammatory diseases, chronic pulmonary obstructive disease, autoimmune disease, diabetes, arterial hypertension, obesity and dyslipidemias was collected on a standardized form. Patients underwent compression ultrasonography (CUS) of the proximal deep veins in both legs to measure the diameter of any residual venous Testing for lupus anticoagulant phenomenon and/or antiphospholipid antibodies and antithrombin, protein C and protein S activities , factor V Leiden and the G20210A mutation in the prothrombin gene was performed at the enrolling centers, as reported before 12 . Subjects found to have antiphospholipid syndrome or antithrombin deficiency were excluded from further analysis and resumed anticoagulation.
Follow-up and study outcomes
All patients with a normal D-d were followed for a maximum duration of 13 months from the assignment visit and were seen at the clinical center every two months over a year when D-d testing was repeated for a maximum of six times. In cases of suspected DVT recurrence, the results of CUS were compared with those of the last available previous examination. A recurrent DVT was diagnosed if a previously fully compressible segment (contralateral or ipsilateral) was no longer compressible or if an increase of at least 4 mm in the diameter of the residual thrombus during compression was detected 10 . When thrombus diameter changed between 1.1 and 3.9 mm, or in cases of high/moderate clinical probability and normal proximal compression ultrasonography, the examination was repeated 5 to 7 days later.
In patients with suspected PE, diagnosis of recurrence was based on objective algorithms 13,14 using clinical probability, ventilation-perfusion lung scanning or helical computed tomography, compression ultrasonography and/or D-d if indicated.
Major bleeding events were defined as bleeds that were retroperitoneal or intracranial, or associated with a decrease in the haemoglobin of The baseline characteristics of the patients are reported in Table 1 . Patients (n=104) who prolonged or resumed VKA for an abnormal D-d either at T0 or at T30 were significantly older, had more co-morbidities and had a longer follow-up than patients who stopped VKAs for a normal D-d at both T0 and T30 (n=243).
RESULTS
Patients
Follow-up and Recurrent Venous Thromboembolism
Recurrences before T30 were observed in 2 patients who stopped VKA for a normal Table 2 illustrates study follow-up from T90 to T390. The rate of recurrence was 22.6% (7/31; 95% CI: 10-41%) in those subjects in whom D-d was abnormal at T90 and 4.6% (9/195; 95% CI: 2-9%) in patients in whom D-d was normal at T90 (p=0.0031).
Recurrence rates were significantly higher in males than in females (15/136: 11% -95% CI:
6-18% vs. 1/107:1%; 95% CI 0-5% P=0.001), while a trend for higher recurrences was observed in subjects with than in those without co-morbidities (10/89: 11.3%; 95% CI: 6-20% vs. 6/136: 4.4% -95% CI: 2-9%; p=0.06). At T210 and at T270, the rate of recurrence was significantly higher in those subjects in whom D-d was abnormal also previously when compared with persistently normal D-d.
For Table 3 shows the recurrence rate according to D-d time course from T90. All recurrent events were idiopathic except one event secondary to trauma in a subject with a normal D-d at T90. The rate of recurrence was significantly higher in subjects in whom Dd became abnormal at T90 and remained abnormal afterwards than in subjects in whom D-d was normal at T90 and remained normal afterwards (p=0.001). However the rate of recurrence was also significantly higher in subjects in whom D-d became abnormal after T90 than in subjects in whom D-d was normal at T90 and remained normal afterwards (p=0.035). Table 4 
Major bleeding
Major hemorrhages were recorded in 5 of the 104 patients who either continued or resumed VKAs for an abnormal D-d at T0 or at T30 (3 gastro-intestinal hemorrhages, 1 retroperitoneal haematoma, 1 fatal intracranial hemorrhage; 4.8%, 95% CI: 2-11%; 3.3% patient-years, 95% CI: 1-7%). In two patients, VKAs were discontinued for severe chronic anemia. One patient died due to sepsis.
DISCUSSION
The previously reported PROLONG randomized study showed that patients with a first For
The results of this study should be evaluated with some caution. First, the trial was prospective, and bias could not be completely minimized, in spite of a blinded central adjudication committee. However, the baseline characteristics of patients who stopped anticoagulation were similar to those of patients who resumed anticoagulation except for age and co-morbidities. The rates of events in treated and untreated patients are similar to those reported in the literature, albeit low, as expected, with large confidence intervals.
Second, some very early recurrences were observed in the first month after Follow-up (days) Cumulative incidence of outcomes %
